To further test this function, we performed viability assays in glioblastoma cells in the presence of proteoliposomes carrying sapC, sapC-PUMA, and sapC-PUMA-DM with the expectation to observe similar cytotoxicity for sapC proteoliposomes as previously reported [12] and increased cytotoxicity for sapC-PUMA proteoliposomes due to the additional killing effect of the PUMABH3 domain. Here, DMPK is linked to glioblastoma.